Trial Profile
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Aug 2021
Price :
$35
*
At a glance
- Drugs Niacin (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- 01 Aug 2021 Results of a pooled analysis assessing the potential mechanisms for this lack of cardioprotection by quantifying the HDL proteome of subjects in 2 niacin clinical trials ( CPC study (Carotid Plaque Composition) and the HDL Proteomics substudy of the AIM-HIGH trial) published in the Arteriosclerosis Thrombosis and Vascular Biology
- 09 Jan 2017 New trial record
- 24 Feb 2012 Status changed from recruiting to completed.